Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients who meet ALL the following criteria can be enrolled:~* Male or female aged at least 18 years,~* With a diagnosis of active Psoriatic Arthritis (PsA),~* For whom the treating physician has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria (refer to the reimbursement conditions mentioned in Section 1.2),~* Able to follow the instructions of the study,~* Having signed an Informed Consent Form (ICF).~Exclusion Criteria:~- Patients who meet AT LEAST one of the following exclusion criteria will be excluded:~* Women who are pregnant, breastfeeding or planning on becoming pregnant,~* Non-menopausal women who are not using an adequate contraception method,~* Patients with hypersensitivity to apremilast or to one of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of apremilast in patients with active PsA (Type: None): Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium

Based on this trial design, predict the completion outcome and termination type (if applicable).